Tesamorelin (5 mg Vial)
Dosing & reconstitution protocol
Quick Reference
Overview
Tesamorelin is a synthetic 44-amino-acid peptide analog of GHRH. FDA-approved for visceral adipose tissue reduction. At 2.0 mg/mL, 1 unit = 0.01 mL = 20 mcg on a U-100 syringe. Evening administration recommended to coincide with nocturnal GH release.
Dosing & Reconstitution Guide
| Phase | Daily Dose | Units | Volume |
|---|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 50 units | 0.50 mL |
| Weeks 2–12+ | 2 mg / 2000 mcg | 100 units | 1.00 mL |
Reconstitution Instructions
Draw 2.5 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl until dissolved (do not shake).
Label and refrigerate at 2–8 °C, protected from light.
Use within 7 days when reconstituted with bacteriostatic water.
This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
- ✓Peptide Vials (Tesamorelin, 5 mg): 23 vials (112 mg total)
- ✓Insulin Syringes (U-100, 1 mL capacity): 56 syringes (7/week)
- ✓Bacteriostatic Water (10 mL): 6 bottles (57.5 mL needed)
- ✓Alcohol Swabs: 2 × 100-count boxes (112 swabs)
Dosing Protocol
Titration
Week 1: 1 mg (1000 mcg) once daily to assess tolerability. Weeks 2+: 2 mg (2000 mcg) once daily (standard FDA-approved dose).
Timing
Evening administration recommended; rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms).
Cycle Length
12–26 weeks; clinical trials support up to 52 weeks with monitoring.
Storage & Handling
- ✓Lyophilized: Store at 2–8 °C; newer formulations stable at 20–25 °C before reconstitution.
- ✓Reconstituted (bacteriostatic water): Refrigerate at 2–8 °C; use within 7 days.
- ✓Reconstituted (sterile water): Use immediately; discard unused portion.
- ✓Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.
Important Notes
- ✓All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.
- ✓Use new sterile insulin syringes for each injection; dispose in a sharps container.
- ✓Rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms).
- ✓Monitor IGF-1 levels periodically; observe blood glucose in diabetic patients.
- ✓Document daily dose and site rotation to maintain consistency.